New drug RC278 targets Hard-to-Treat solid tumors in early trial

NCT ID NCT07105215

Recruiting now Disease control Sponsor: RemeGen Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new drug called RC278 in people with advanced solid tumors that cannot be removed by surgery or have spread. The main goals are to find a safe dose and see if the drug can shrink tumors. About 312 adults aged 18 to 75 with good overall health are being recruited.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED UNRESECTABLE OR METASTATIC MALIGNANT SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metastatic malignant neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOLID TUMORS

Contacts and locations

Locations

Anyang Cancer Hospital
RECRUITING

Luoyan, Henan, China
Cancer Hospital Chinese Academy of Medical Sciences
RECRUITING

Beijing, Beijing Municipality, China
Cancer Hospital of Shandong First Medical University
RECRUITING

Jinan, China
Fudan University Shanghai Cancer Center
RECRUITING

Shanghai, Shanghai Municipality, China
Fujian Cancer Hospital
RECRUITING

Fuzhou, Fujian, China
Fujian Cancer Hospital
RECRUITING

Fuzhou, Fujian, China
Fujian Medical University Union Hospital
RECRUITING

Fuzhou, Fujian, China
Guangxi Medical University Cancer Hospital & Guangxi Cancer Institute
RECRUITING

Nanning, Guangxi, China
Harbin Medical University Cancer Hospital
RECRUITING

Harbin, Heilongjiang, China
Henan Cancer Hospital
RECRUITING

Zhengzhou, China
Hubei Cancer Hospital
RECRUITING

Wuhan, Hubei, China
Hunan Cancer Hospital
RECRUITING

Changsha, Hunan, China
Hunan Cancer Hospital
RECRUITING

Changsha, Hunan, China
Hunan Cancer Hospital
RECRUITING

Changsha, Hunan, China
Hunan Cancer Hospital
RECRUITING

Changsha, Hunan, China
Jiangsu Province Hospital
RECRUITING

Nanjing, Jiangsu, China
Jinan Central Hospital
RECRUITING

Jinan, China
Liaoning Cancer Hospital & Institute
RECRUITING

Shenyang, Liaoning, China
Nanyang Second General Hospital
RECRUITING

Nanyang, Henan, China
Shanxi Cancer Hospital
RECRUITING

Taiyuan, China
Sir Run Run Shaw Hospital, affiliated with Zhejiang University School of Medicine
RECRUITING

Hangzhou, Zhejiang, China
Sun Yat-sen University Cancer Center
RECRUITING

Guangzhou, China
Taizhou Hospital of Zhejiang Province
RECRUITING

Taizhou, Zhejiang, China
The Affiliated Hospital of Xuzhou Medical University
RECRUITING

Xuzhou, Jiangsu, China
The First Affiliated Hospital of Henan University of Science &Technology
RECRUITING

Luoyang, Henan, China
The First Affiliated Hospital of Nanchang University
RECRUITING

Nanchang, Jiangxi, China
The First Affiliated Hospital of Xiamen University
RECRUITING

Xiamen, Fujian, China
The First Affiliated Hospital of Xinxiang Medical University
RECRUITING

Xinxiang, Henan, China
The First Affiliated Hospital of Zhengzhou University
RECRUITING

Zhengzhou, Henan, China
The First Affiliated Hospital, Zhejiang University School Of Medicine
RECRUITING

Hangzhou, China
The Second Affiliated Hospital of Guilin Medical University
RECRUITING

Guilin, Guangxi, China
The first Hospital of China Medical University
RECRUITING

Shenyang, Liaoning, China
Tongji Hospital, Tongji Medical College of HUST, China
RECRUITING

Wuhan, Hubei, China
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, China
RECRUITING

Wuhan, Hu'Nan, China
West China Hospital of Sichuan University
RECRUITING

Chengdu, Sichuan, China
Xuzhou Central Hospital
RECRUITING

Xuzhou, Jiangsu, China
Yunnan Tumor Hospital
RECRUITING

Kunming, Yunnan, China
Zhejiang Cancer Hospital
RECRUITING

Hangzhou, Zhejiang, China
Zhongshan Hospital, Fudan University
RECRUITING

Shanghai, Shanghai Municipality, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.